Linezolid induced delirium in the absence of serotonin syndrome:
a psychiatric consultation/liaison case report
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Abstract
Delirium is one of the most common mental illnesses that can affect elderly patients and patients
with advanced medical problems. Because these patients are frequently on multiple medications
and/or are more sensitive to medications secondary to their age, interactions with current
medications, or existing medical problems, medication toxicity is frequently the etiology behind
their delirium. This is a case report of a patient admitted for cellulitis that developed delirium
from Linezolid however did not develop any other signs or symptoms of serotonin syndrome; a
known side effect of Linezolid. This distinctive case highlights the importance of a careful
analysis of a patient’s medications for potential deliriogenicity as well as the value of using a
validated tool for assessing and following up a patient with suspected delirium. Specifically, this
case should give clinicians warrant for suspicion of Linezolid as the cause of a patient’s delirium
regardless of the presence or absence of serotonin syndrome.
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Introduction
Nearly 30 percent of all older medical patients experience delirium at some point during their
hospitalization and this is one of the most common mental illnesses to develop in the elderly and
in patients with advanced medical problems.1 Early identification that patients are in a delirious
state and the prompt treatment of the medical etiology or stopping of the deliriogenic agent are
crucial in decreasing morbidity and mortality in these patients. An important first step in the
evaluation of a delirious patient is a thorough review of the patient’s medication list for
medications known to cause delirium (see Table 1) as approximately 30 percent of cases are
drug-induced.2 Additionally, the use of a validated and standardized assessment tool can be
valuable in identifying and monitoring a delirious patient.3 Lastly, formulation of a
comprehensive working differential diagnosis is critical in managing these patients.

Table 1. Potential Deliriogenic Medications

Analgesics

Antidepressants

NSAIDs
Opioids-specifically meperidine

Mirtazapine
SSRI’s
TCA’s

Antibiotics
Acyclovir
Aminoglycosides
Amphotericin B
Antimalarial drugs
Cephalosporins
Cycloserine
Fluoroquinolones
Isoniazid

Antiarrhythmics
Beta blockers
Clonidine
Digoxin
Diuretics
Methyldopa

Corticosteroids
Dopamine agonists

Interferon
Linezolid
Macrolides
Metronidazole
Nalidixic acid
Penicillins
Rifampin

Amantadine
Bromocriptine
Levodopa
Pergolide
Pramipexole
Ropinirole

Sulfonamides

Antiemetics
Antispasmodics
Histamine-2 receptor blockers
Loperamide

Anticholinergics
Atropine
Benztropine
Diphenhydramine
Scopolamine
Trihexyphenidyl

Anticonvulsants
Carbamazepine
levetiracetam
Phenytoin
Valproate
Vigabatrin

Gastrointestinal agents

Herbal supplements
Belladonna extract
Henbane
Mandrake
Jimson weed
St. John’s Wort
Valerian
Phenothiazines
*not a complete list, all medication should be
considered.

This case report focuses on Linezolid, an oxazolidinone antibiotic that also has reversible
monoamine oxidase (MAO) inhibition properties. It is well known that when used
concomitantly with other serotonergic medications, Linezolid increases the patient’s
susceptibility towards developing serotonin syndrome. Also, inhibition of mammalian
mitochondrial protein synthesis by oxazolidinones including linezolid has been studied and
reported; this is believed to be secondary to oxidative injury from prolonged use.
While it has been theorized that the increase in catecholamines from monoamine oxidase
inhibition could also be deliriogenic, this case is unique in that similar cases have not been
commonly documented in the literature where Linezolid is the cause of delirium in the complete
absence of serotonin syndrome.
CASE REPORT
A morbidly obese (BMI of 45) Caucasian female in her mid-fifties who smokes about two packs
per day presented to her local emergency room with complaints of persistent moderate left lower
extremity pain secondary to cellulitis that had been associated with nausea, vomiting, and fever
for the past three days. She has had recurrent cellulitis and MRSA infections along with a
medical history significant for poorly controlled DM2, CKD stage III, anemia of chronic disease,
COPD, and hypertension. Patient does not have past medical history of any psychiatric illnesses
and takes no psychotropic medications.
She was appropriately admitted from the emergency room to medicine service and was started on
Vancomycin and Piperacillin/Tazobactam and given IV fluids; patient’s lactic acid was mildly
elevated upon admission (2.3 mmol/L) but normalized with the use of normal saline. Her
cellulitis was demarcated to track improvement and MRI and venous duplex scans were
performed to rule out osteomyelitis, abscess, and deep venous thrombosis; all were negative.
After several days the patient began to improve clinically as her vitals returned to normal,
WBC’s trended down, and the erythema receded to approximately the mid-calf. It was at this
time in her hospital course that she developed an acute kidney injury. Nephrology thought this
was likely due to intrinsic renal disease and recommended stopping Vancomycin and
Piperacillin/Tazobactam. Her acute kidney injury resolved and an infectious disease consultation
recommended starting Linezolid. The patient was started on Linezolid 600mg IV, given two
doses, and over the next 24 hours developed an altered mental status. Psychiatry
consultation/liaison service was consulted to evaluate the patient at that time.
Psychiatry evaluation and assessment included the Delirium Rating Scale (DRS-R-98) which
was used to evaluate and follow up the patient. The patient scored 30 / 39 on the severity scale
and 33/46 total score. Clinically she had day-night reversal, was completely disoriented and
inattentive, was having auditory and visual hallucinations, exhibited a lability of affect with
hysterical laughing, crying, and yelling; she required a 24 hour sitter and needed assisted feeds.
The teams’ differential diagnosis included serotonin syndrome secondary to the newly started
Linezolid or a delirium secondary to sepsis, uremic encephalopathy, or medications.
Serotonin syndrome was ruled out by using The Hunter Serotonin Toxicity Criteria4. While the
patient had been administered Linezolid, a serotoninergic medication, she was not on any other

serotonergic medications, and was afebrile and without tremor, rigidity, or clonus. Sepsis was
ruled out as the cause of her delirium as her sepsis was resolving when she became delirious; her
WBC’s had been trending down, and her vital signs had been stable for more than 24 hours.
Uremia was not likely the cause of her delirium as her BUN was never more than 60, and by the
time she was switched to Linezolid her creatinine levels had returned to baseline. The patient
was not on any other medications likely to be deliriogenic and it was determined that it was
likely the Linezolid causing the patient’s delirium despite the absence of any serotonin syndrome
symptoms. Linezolid was stopped in the initial evaluation by the consult team and within 24
hours of discontinuation the patient’s mental status had returned to her baseline. On the
Delirium Rating Scale the patient now scored 6 on the severity scale and 7 on the total scale, and
this did not fluctuate for the rest of her hospital stay. (See Figure 1)

Figure 1

DISCUSSION
This unique case demonstrates the two key clinical aspects of care in a patient with delirium: the
use of a standardized assessment tool to identify and follow up a patient with delirium and the
formulation of a comprehensive differential diagnosis that includes a thorough analysis of the
patient’s medications. The use of a validated assessment tool for delirium, such as the DRS-R98,
can help give a much clearer clinical picture of the delirious patient’s fluctuations and response
to treatment.3 Indeed, the Delirium Rating Scale R-98 was valuable in determining the effect of
our intervention with this patient and confirming the suspected etiology; this scale can be
administered by physicians or nurses. Although the pathophysiology of delirium is poorly

understood, theoretically any medication that can cause a disruption in the normal
neurotransmitter pathways can precipitate a delirium. Delirium is essentially the final common
symptom of multiple neurotransmitter abnormalities including the acetylcholine, serotonin,
glutamate, GABA, and dopamine neural pathways leading to increased glutamate, decreased
GABA, and increased dopamine.5 Linezolid acts to inhibit both MAO-A and MAO-B
reversibly. MAO-A inhibition primarily increases available serotonin, whereas MAO-B
inhibition primarily increases available dopamine and norepinephrine. It is this separate MAO-A
and MAO-B binding of Linezolid that may be why our patient developed her delirium without
serotonin syndrome. Clinicians should be mindful that in patients treated with Linezolid, who
subsequently develop altered mental status, the discontinuation of Linezolid should be
considered regardless of the presence or absence of serotonin syndrome.
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